Q2 2018 13F Holders as of 6/30/2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236M
-
Number of holders
-
135
-
Total 13F shares, excl. options
-
42.4M
-
Shares change
-
-542K
-
Total reported value, excl. options
-
$423M
-
Value change
-
-$3.99M
-
Put/Call ratio
-
0.05
-
Number of buys
-
70
-
Number of sells
-
-62
-
Price
-
$9.98
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q2 2018
166 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q2 2018.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 135 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 42.4M shares
of 236M outstanding shares and own 17.95% of the company stock.
Largest 10 shareholders include BlackRock Inc. (5.02M shares), Nantahala Capital Management, LLC (4.52M shares), Novo Holdings A/S (3.1M shares), EAGLE ASSET MANAGEMENT INC (2.82M shares), VANGUARD GROUP INC (2.58M shares), PERCEPTIVE ADVISORS LLC (2.22M shares), CARILLON TOWER ADVISERS, INC. (2.06M shares), STATE STREET CORP (1.93M shares), RENAISSANCE TECHNOLOGIES LLC (1.87M shares), and MORGAN STANLEY (1.39M shares).
This table shows the top 135 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.